Home/Pipeline/Monoclonal Antibody Biosimilar (Anti‑TNF)

Monoclonal Antibody Biosimilar (Anti‑TNF)

Rheumatoid Arthritis

Phase 1Active

Key Facts

Indication

Rheumatoid Arthritis

Phase

Phase 1

Status

Active

Company

Indian pharma company delivering generics and biosimilars with a strong API manufacturing base.

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
ERNA-201	Eterna Therapeutics	Preclinical	Active Discovery/Research
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
LFD-200	Lifordi Immunotherapeutics	Phase 1	Active
MEV-N01	Mesenbio	Pre-clinical	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active
AX-158	Artax Biopharma	Phase 2	Active